Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

被引：0
|
作者：
Friedrich, S. [1 ]
Chua, L. [1 ]
Zhang, X. C. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P519
引用
收藏
页码：646 / 646
页数：1
相关论文
共 50 条
  • [21] PHARMACOKINETICS AND EXPOSURE-RESPONSE OF TOFACITINIB IN A PHASE 3 MAINTENANCE STUDY IN ULCERATIVE COLITIS PATIENTS
    Mukherjee, Arnab
    D'Haens, Geert R.
    Sandborn, William J.
    Tsuchiwata, Shinichi
    Vong, Camille
    Deng, Chenhui
    Xie, Rujia
    Hazra, Anasuya
    Martin, Steven W.
    Friedman, Gary
    Niezychowski, Wojciech
    Su, Chinyu
    GASTROENTEROLOGY, 2017, 152 (05) : S595 - S596
  • [22] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
    Danese, Silvio
    Vermeire, Severine
    Zhou, Wen
    Pangan, Aileen L.
    Siffledeen, Jesse
    Greenbloom, Susan
    Hebuterne, Xavier
    D'Haens, Geert
    Nakase, Hiroshi
    Panes, Julian
    Higgins, Peter D. R.
    Juillerat, Pascal
    Lindsay, James O.
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Reinisch, Walter
    Chen, Min-Hu
    Gonzalez, Yuri Sanchez
    Huang, Bidan
    Xie, Wangang
    Liu, John
    Weinreich, Michael A.
    Panaccione, Remo
    LANCET, 2022, 399 (10341): : 2113 - 2128
  • [23] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [24] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [25] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
  • [26] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
    Sandborn, W. J.
    Sands, B.
    Kobayashi, T.
    Tuttle, J.
    Schmitz, J.
    Durante, M.
    Higgs, R.
    Canavan, J. B.
    Siegel, R.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
  • [27] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [28] Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Strauss, Richard
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 157 - 174
  • [29] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Long, Millie D.
    Armuzzi, Alessandro
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [30] Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies
    Adedokun, Omoniyi
    Xu, Zhenhua
    Marano, Colleen
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Ford, Joyce
    Zhou, Honghui
    Davis, Hugh
    Colombel, Jean-Frederic
    Reinisch, Walter
    Feagan, Brian
    Rutgeerts, Paul
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S517 - S517
12345